Low-dose tocilizumab for acute chest syndrome in sickle cell disease

You may qualify if

• Adults ≥ 12 years of age
• Prior diagnosis of sickle cell disease (Hb SS, Hb SC, Hb Sb+, and Hb Sb0)

You can't join if

• Pregnant patients or breastfeeding mothers.
• Prior treatment with gene therapy or a stem cell transplant.
• Current enrollment in a clinical trial involving an FDA-regulated drug or biologic.
• Current neutropenia (absolute neutrophil count < 1000/mm^3)
• Current thrombocytopenia (platelet count < 50,000 mm^3)
• Aspartate aminotransferase (AST) or alanine transaminase (ALT) > 10 times the upper limit of normal (ULN)
• History of tuberculosis (TB).
• Positive purified protein derivative (PPD) TB screening test.
• On active therapy with a Bruton's tyrosine kinase-targeted agent, which include the following: Acalabrutinib, Ibrutinib, Zanubrutinib
• On active therapy with a JAK2-targeted agent, which include the following: Baricitinib, Ruxolitinib, Tofacitinib, Upadacitinib
• Any of the following biologic immunosuppressive agent (and any biosimilar versions thereof) administered in the past 6 months: Abatacept, Adalimumab, Alemtuzumab, Atezolizumab, Belimumab, Blinatumomab, Brentuximab, Certolizumab, Daratumumab, Durvalumab, Eculizumab, Elotuzumab, Etanercept, Gemtuzumab, Golimumab, Ibritumomab, Infliximab, Inotuzumab, Ipilimumab, Ixekizumab, Moxetumomab, Nivolumab, Obinutuzumab, Ocrelizumab, Ofatumumab, Pembrolizumab, Polatuzumab, Rituximab, Sarilumab, Secukinumab, Tocilizumab, Tositumumab, Tremelimumab, Urelumab, Ustekinumab